These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 10147037)

  • 1. Principles of pharmacoeconomic analysis of drug therapy.
    Freund DA; Dittus RS
    Pharmacoeconomics; 1992 Jan; 1(1):20-31. PubMed ID: 10147037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for performing a pharmacoeconomic analysis.
    Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
    Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
    Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
    Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Introduction to the theory of pharmaco-economics].
    Kurz X; Dresse A
    Rev Med Liege; 1998 May; 53(5):230-5. PubMed ID: 9689873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions.
    Tonin FS; Aznar-Lou I; Pontinha VM; Pontarolo R; Fernandez-Llimos F
    Pharm Pract (Granada); 2021; 19(1):2302. PubMed ID: 33727994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinician's perspective on pharmacoeconomics and rheumatology.
    Thielscher C
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S91-5. PubMed ID: 23078957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulary and economic considerations in the selection of antiplatelet agents.
    Crane VS
    Am J Health Syst Pharm; 1998 Oct; 55(19 Suppl 1):S28-31. PubMed ID: 9784800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence of pharmacoeconomic studies to national guidelines in the Netherlands.
    Atthobari J; Bos JM; Boersma C; Brouwers JR; de Jong-van den Berg LT; Postma MJ
    Pharm World Sci; 2005 Oct; 27(5):364-70. PubMed ID: 16341742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
    Anton SF; Revicki DA
    Psychopharmacol Bull; 1995; 31(2):249-58. PubMed ID: 7491376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics.
    Sule NS; Nerurkar RP; Kamath SA
    J Assoc Physicians India; 2002 Aug; 50():1057-62. PubMed ID: 12421032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical economics in clinical trials: the measurement of cost and outcomes in the assessment of clinical services through clinical trials.
    Schulman KA; Ohishi A; Park J; Glick HA; Eisenberg JM
    Keio J Med; 1999 Mar; 48(1):1-11. PubMed ID: 10206013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy evaluation, patient distribution, and cost-outcomes ratios.
    Langley PC
    Clin Ther; 1995; 17(2):341-7. PubMed ID: 7614534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM; Ereshefsky L
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on pharmacoeconomics in transplantation.
    Cavanaugh TM; Martin JE
    Prog Transplant; 2007 Jun; 17(2):103-19; quiz 120. PubMed ID: 17624133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fundamentals of clinical economics in health interventions.
    Awasthi S
    Indian J Pediatr; 2000 May; 67(5):352-7. PubMed ID: 10885208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Methodology of pharmacoeconomic studies in oncology].
    Ballatori E
    Recenti Prog Med; 2008 Jan; 99(1):42-7. PubMed ID: 18389873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.
    Brereton N; Bodger K; Kamm MA; Hodgkins P; Yan S; Akehurst R
    J Med Econ; 2010 Mar; 13(1):148-61. PubMed ID: 20141380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.